Keywords: Ensemble Thera, Boehringer Ingelheim, Drug discovery, Macrocycles
Ensemble Thera in deal worth a potential $186 million with Boehringer Ingelheim
Article | 05 November 2012
USA-based drug discovery firm Ensemble Therapeutics says it has initiated a research collaboration with family-owned German drug major Boehringer Ingelheim ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- New study shows UCB's Neupro reduces NSBP in RLS patient
